Type 2 diabetes patients who receive self-donated (autologous) bone marrow stem cells require less insulin, a new study revealed.
The research, published in Cell Transplantation, was carried out in India and looked at the safety and efficacy of autologous transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M).
Study corresponding author Anil Bhansali, PhD, professor and head of the Endocrinology Department at the Post Graduate Institute of Medical Education in Chandrigarh, India, said:
"There is growing interest in the scientific community for cellular therapies that use bone marrow-derived cells for the treatment of type 2 diabetes mellitus and its complications. But the potential of stem cell therapy for this disease is yet to be fully explored."
Although there is an increasing interest in using stem cell transplantation to treat people with this condition, there has been little research observing the benefit of bone marrow-derived stem cells.
Read More: http://www.medicalnewstoday.com/articles/262707.php
0 σχόλια:
Δημοσίευση σχολίου